quinidine has been researched along with dextromethorphan in 115 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (12.17) | 18.2507 |
| 2000's | 36 (31.30) | 29.6817 |
| 2010's | 55 (47.83) | 24.3611 |
| 2020's | 10 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Commandeur, JN; Funae, Y; Hiroi, T; ter Laak, AM; Venhorst, J; Vermeulen, NP | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, LZ; Huang, X; Liu, MM; Liu, XH; Ma, D; Shi, JB; Shu, HY; Wu, J; Yu, YL | 1 |
| Britto, MR; Smith, RA; Valderhaug, KL; Wedlund, PJ; Zhang, Y | 1 |
| Belghiti, J; Larrey, D; Lettéron, P; Loeper, J; Maurel, P; Pessayre, D; Tinel, M | 1 |
| Blake, CL; Ching, MS; Ellis, SW; Ghabrial, H; Lennard, MS; Smallwood, RA; Tucker, GT | 1 |
| Kalow, W; Otton, SV; Schadel, M; Sellers, EM; Wu, D | 1 |
| Broly, F; Courseau, C; Lhermitte, M; Libersa, C; Vandamme, N | 1 |
| Bochner, F; Kerry, NL; Mikus, G; Somogyi, AA | 1 |
| Bochner, F; Chen, ZR; Somogyi, AA | 1 |
| Buchert, ET; Chen, CP; Chung, HM; Hou, ZY; Lai, MD; Pickle, LW; Woosley, RL; Yang, WC | 1 |
| Bochner, F; Capon, DA; Danz, C; Kerry, N; Mikus, G; Somogyi, AA | 1 |
| Baylon, GJ; Busto, UE; Cheung, SW; Kaplan, HL; Otton, SV; Sellers, EM; Somer, G | 1 |
| Fogelman, SM; Greenblatt, DJ; Schmider, J; Shader, RI; von Moltke, LL | 1 |
| Granda, BW; Grassi, JM; Greenblatt, DJ; Harmatz, JS; Schmider, J; Shader, RI; Venkatakrishnan, K; von Moltke, LL | 1 |
| Allaz, AF; Dayer, P; Desmeules, JA; Oestreicher, MK; Piguet, V | 1 |
| Abdul Manap, R; Gregory, A; Kelm, GR; Lennard, MS; Meller, ST; Morice, AH; Rostami-Hodjegan, A; Tucker, GT; Wright, CE | 1 |
| Abdul-Manap, R; Moghadamnia, AA; Morice, AH; Rostami-Hodjegan, A; Tucker, GT; Wright, CE | 1 |
| Axelsson, H; Floby, E; Granhall, C; Jaksch, Y; Sohlenius-Sternbeck, AK; Svedling, M | 1 |
| Di Marco, A; Laufer, R; Yao, D | 1 |
| Berg, JE; Marier, JF; Pope, LE; Stiles, M; Vachon, P; Yakatan, GJ | 1 |
| Berg, JE; Khalil, MH; Pope, LE; Sellers, EM; Stiles, M; Yakatan, GJ | 1 |
| Appel, SH; Berg, JE; Bradley, WG; Brooks, BR; Olney, RK; Pope, LE; Smith, RA; Thisted, RA | 1 |
| Meininger, V | 1 |
| Bhoopathy, S; Karnes, HT; Unger, SE; Xin, B | 1 |
| Brooks, BR; Smith, RA | 1 |
| Hingorani, VN; Kittrelle, JP | 1 |
| Iwasaki, K; Murase, S; Shimada, K; Takashima, T | 1 |
| Weintraub, D | 1 |
| Pope, LE; Schiffer, R | 1 |
| Haining, RL; Yu, AM | 1 |
| Achiron, A; Berg, JE; Dietrich, DW; Fletcher, M; Mandler, RN; Miller, A; Panitch, HS; Pope, LE; Smith, RA; Thisted, RA; Vollmer, TL; Wymer, JP; Wynn, DR | 1 |
| Miller, A | 1 |
| Bellward, GD; Chang, TK; Levine, M; Madeira, M; Mirfazaelian, A | 1 |
| Smith, RA | 1 |
| Berg, JE; Culligan, NW; Gerard, G; Klaff, L; Pope, LE; Schwartz, SL; Thisted, RA; Wymer, JP | 1 |
| Hauser, SL; Johnston, SC | 1 |
| Hammond, C; Hargreaves, JA; Rostami-Hodjegan, A; Swales, J; Van, LM; Wilson, C | 1 |
| Huang, H; Lin, L; Qi, X; Zhang, P; Zhong, D | 1 |
| Brooks, BR | 1 |
| Mäenpää, J; Pelkonen, O; Tolonen, A; Turpeinen, M; Uusitalo, J; Volotinen, M | 1 |
| Miller, A; Panitch, H | 1 |
| Guo, B; He, MM; Li, C; Liu, H; Shen, H; Wang, L; Wrighton, SA | 1 |
| Hellum, BH; Nilsen, OG | 1 |
| Martin, CM | 1 |
| Bisaga, A; Daniel, WA; Kos, T; Popik, P; Wójcikowski, J | 1 |
| Rosen, H | 1 |
| Curcio, R; Nicoli, R; Rudaz, S; Veuthey, JL | 1 |
| Haiman, G; Miller, A; Pratt, H | 1 |
| Drmić, S; Mimica, N; Presecki, P | 1 |
| Busto, U; Sellers, EM; Tyndale, RF; Zawertailo, LA | 1 |
| Olney, N; Rosen, H | 1 |
| Brooks, BR; Cummings, J; Hepner, A; Kaye, R; Pioro, EP; Schiffer, R; Thisted, RA; Wynn, D | 1 |
| Garnock-Jones, KP | 1 |
| Miller, A; Pratt, H; Schiffer, RB | 1 |
| Pioro, EP | 1 |
| Pope, LE; Schoedel, KA; Sellers, EM | 1 |
| Hepner, A; Pope, LE; Shaibani, AI; Thisted, R | 1 |
| Kwan, YW; Or, PM; Wan, DC; Wang, Y; Yeung, JH; Zhou, X | 1 |
| Bartlett, C; Pope, LE; Schoedel, KA; Sellers, EM | 1 |
| Chabert, J; Daali, Y; Dayer, P; Desmeules, JA; Ehret, GB; Forster, A; Fritschy, D; Gex-Fabry, M; Moursli, F; Piguet, V; Rebsamen, M; Rossier, MF; Wolff, A | 1 |
| Stahl, SM | 2 |
| Bae, SH; Bae, SK; Cho, DY; Kim, BT; Kim, YW; Lee, JK | 1 |
| Healy, JR; Matsumoto, RR; Nguyen, L; Robson, MJ; Scandinaro, AL | 1 |
| Casselman, J; Patatanian, E | 1 |
| Kelly, TF; Lieberman, DZ | 1 |
| Appel, SH; Formella, AE; Lomen-Hoerth, C; Pattee, GL; Pope, LE; Wymer, JP | 1 |
| Ferrara, JM | 1 |
| Berkovich, RR; Lyubashina, OA; Panteleev, SS; Sokolov, AY | 1 |
| Deeks, ED; Yang, LP | 1 |
| A, J; Ho, RJ; Liu, J; Liu, K; Peng, Y; Qi, H; Shang, L; Sun, J; Sun, Y; Wang, G; Wu, H; Xiao, Y; Zhang, F; Zhang, X; Zhong, Y; Zhu, J | 1 |
| Matsumoto, RR; Nguyen, L | 1 |
| Antonsdottir, IM; Keltz, M; Porsteinsson, AP; Smith, J | 1 |
| Wise, J | 1 |
| Cutler, AJ; D'Amico, S; Davis, CS; Doody, RS; Ledon, F; Shin, P; Siffert, J; Yonan, C | 1 |
| Ballard, C; Corbett, A | 1 |
| Roman, MW | 1 |
| Carroll, BT; Denysenko, L; Mitchell, JL; Turner, J | 1 |
| Badyra, B; Kudolo, J; Lisowski, B; Polak, S; Wiśniowska, B | 1 |
| Newman, JC; Steinman, MA | 1 |
| Cummings, JL; Siffert, J | 1 |
| Garcia-Baran, D; Geers, M; Johnson, TM; Shen, J; Wagner, J | 1 |
| Matsumoto, RR; Pope, LE; Siffert, J; Taylor, CP; Traynelis, SF | 1 |
| Alexander, DN; Cutler, AJ; D'Amico, S; Davis, CS; Doody, RS; Formella, AE; Hammond, FM; Ledon, F; Sauve, W; Shin, P; Siffert, J; Yonan, C; Zorowitz, RD | 1 |
| Crumpacker, DW | 1 |
| Garay, RP; Grossberg, GT | 1 |
| Reiman, AT; Schrader, JV; Wahler, RG | 1 |
| Delvadia, P; Giri, P; Gupta, L; Lad, K; Patel, HM; Patel, N; Srinivas, NR; Trivedi, P | 1 |
| Sauvé, WM | 1 |
| Cudkowicz, M; Goslin, K; Macklin, EA; Meekins, G; Myers, K; Pattee, G; Pioro, E; Schoenfeld, D; Sirdofsky, M; Smith, R; Wymer, J; Yu, H | 1 |
| Charpeaud, T; Citrome, L; Correll, CU; Garay, RP; Hameg, A; Llorca, PM; Zarate, CA | 1 |
| Brodsky, M; Factor, SA; Fox, SH; Knowles, N; Lang, AE; Metman, LV; Nutt, JG; Pope, LE; Siffert, J | 1 |
| Ahle, G; Charney, DS; Collins, KA; Iosifescu, DV; Kiraly, DD; Murrough, JW; Sayed, S; Soleimani, L; Wade, E; Welch, A | 1 |
| Chen, Q; Ermann, A; Shad, MU | 1 |
| Davis, C; Formella, AE; Hammond, FM; Ledon, F; Sauve, W | 1 |
| Bell, JS; Chaiyakunapruk, N; Hilmer, SN; Kongpakwattana, K; Sawangjit, R; Tawankanjanachot, I | 1 |
| Calcagno, HE; Chen, Q; Shad, M | 1 |
| Benabides, B; Chez, M; Hankins, A; Kile, S; Lepage, C; Parise, C | 1 |
| Allison, KM; Berry, JD; Cordella, C; Green, JR; Macklin, EA; Pattee, GL; Pioro, EP; Richburg, BD; Smith, RA | 1 |
| Fralick, M; Kesselheim, AS; Sacks, CA | 1 |
| Batty, R; Clay, FJ; Hicks, AJ; Hopwood, M; Jayaram, M; Perry, LA; Ponsford, JL | 1 |
| Heydari, A; Jamali, H | 1 |
| Hayashi, M; Hirasawa-Inoue, A; Matsumoto, N; Matsumura, Y; Mizuguchi, T; Shirai, K; Sugai, K; Takase, C; Watanabe, A; Watanabe, T | 1 |
| Garrett, PI; Hillhouse, TM; Honeycutt, SC; Peterson, AM; Saavedra, JS; White, JW | 1 |
| Nguyen, D; Young, FG | 1 |
| Burés, E; Ferrer, S; Luis Díaz, J; Sancho, J; Servera, E; Signes-Costa, J; Torrecilla, T | 1 |
| Kverno, K | 1 |
| Locatelli, E; Plowman, EK; Tabor Gray, L; Vasilopoulos, T; Wymer, J | 1 |
22 review(s) available for quinidine and dextromethorphan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan.
Topics: Clinical Trials as Topic; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Drug Combinations; Drug Synergism; Drugs, Investigational; Humans; Quinidine; Receptors, N-Methyl-D-Aspartate; Receptors, sigma | 2005 |
Review of pseudobulbar affect including a novel and potential therapy.
Topics: Analgesics, Non-Narcotic; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Drug Therapy, Combination; Humans; Mood Disorders; Pseudobulbar Palsy; Quinidine | 2005 |
Pseudobulbar affect in multiple sclerosis: toward the development of innovative therapeutic strategies.
Topics: Adrenergic alpha-Antagonists; Dextromethorphan; Emotions; Excitatory Amino Acid Antagonists; Humans; Mood Disorders; Multiple Sclerosis; Quinidine | 2006 |
Dextromethorphan/quinidine: a novel dextromethorphan product for the treatment of emotional lability.
Topics: Affective Symptoms; Biological Availability; Dextromethorphan; Drug Therapy, Combination; Humans; Mood Disorders; Quinidine | 2006 |
Involuntary emotional expression disorder: treating the untreated.
Topics: Affective Symptoms; Antidepressive Agents; Clinical Trials as Topic; Dextromethorphan; Dopamine Agents; Drug Therapy, Combination; Humans; Psychotropic Drugs; Quinidine; Treatment Outcome | 2007 |
Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect.
Topics: Animals; Brain; Dextromethorphan; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Humans; Multiple Sclerosis; Pseudobulbar Palsy; Quinidine | 2007 |
Dextromethorphan/quinidine sulfate for pseudobulbar affect.
Topics: Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Dextromethorphan; Drug Combinations; Humans; Pseudobulbar Palsy; Quinidine; Selective Serotonin Reuptake Inhibitors | 2008 |
AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.
Topics: Animals; Clinical Trials as Topic; Dextromethorphan; Diabetic Neuropathies; Drug Combinations; Humans; Mood Disorders; Quinidine | 2010 |
Dextromethorphan/quinidine: in pseudobulbar affect.
Topics: Amyotrophic Lateral Sclerosis; Crying; Dextromethorphan; Drug Combinations; Emotions; Female; Humans; Laughter; Male; Mood Disorders; Multiple Sclerosis; Quinidine | 2011 |
Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments.
Topics: Adrenergic alpha-Antagonists; Brain; Clinical Trials as Topic; Crying; Dextromethorphan; Excitatory Amino Acid Antagonists; Humans; Laughter; Pseudobulbar Palsy; Quinidine; Synaptic Transmission | 2011 |
Current concepts in the pharmacotherapy of pseudobulbar affect.
Topics: Antidepressive Agents; Crying; Dextromethorphan; Drug Combinations; Humans; Laughter; Mood Disorders; Off-Label Use; Quinidine | 2011 |
Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
Topics: Clinical Trials as Topic; Crying; Dextromethorphan; Drug Combinations; Excitatory Amino Acid Antagonists; Humans; Laughter; Pseudobulbar Palsy; Quinidine; Receptors, sigma; Sigma-1 Receptor; Treatment Outcome | 2014 |
Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.
Topics: Adult; Dextromethorphan; Drug Combinations; Humans; Mood Disorders; Nervous System Diseases; Quinidine | 2015 |
Advancements in the treatment of agitation in Alzheimer's disease.
Topics: Alzheimer Disease; Cannabinoid Receptor Agonists; Cannabinoids; Citalopram; Clinical Trials, Phase III as Topic; Dextromethorphan; Drug Combinations; Humans; Psychomotor Agitation; Quinidine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2015 |
Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use.
Topics: Animals; Dextromethorphan; Drug Combinations; Drug Synergism; Humans; Norepinephrine; Quinidine; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Receptors, sigma; Serotonin Plasma Membrane Transport Proteins; Sigma-1 Receptor | 2016 |
Enhancing Approaches to the Identification and Management of Pseudobulbar Affect.
Topics: Affective Symptoms; Crying; Dextromethorphan; Drug Combinations; Female; Humans; Laughter; Middle Aged; Multiple Sclerosis; Neurotransmitter Agents; Quinidine | 2016 |
AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.
Topics: Alzheimer Disease; Animals; Brain; Deuterium; Dextromethorphan; Drug Combinations; Humans; Psychomotor Agitation; Quinidine; Randomized Controlled Trials as Topic; Tissue Distribution; Treatment Outcome | 2017 |
Recognizing and treating pseudobulbar affect.
Topics: Dextromethorphan; Drug Combinations; Early Diagnosis; Excitatory Amino Acid Antagonists; Humans; Pseudobulbar Palsy; Quinidine | 2016 |
Investigational drugs in recent clinical trials for treatment-resistant depression.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depression; Depressive Disorder, Treatment-Resistant; Dextromethorphan; Drug Combinations; Drugs, Investigational; Humans; Quinidine | 2017 |
Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Dementia; Dextromethorphan; Drug Combinations; Humans; Network Meta-Analysis; Psychometrics; Psychomotor Agitation; Quinidine; Randomized Controlled Trials as Topic; Risperidone; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2018 |
Pharmacotherapy for the Pseudobulbar Affect in Individuals Who Have Sustained a Traumatic Brain Injury: a Systematic Review.
Topics: Affective Symptoms; Brain Injuries, Traumatic; Dextromethorphan; Drug Combinations; Humans; Neurotransmitter Agents; Quinidine | 2020 |
23 trial(s) available for quinidine and dextromethorphan
| Article | Year |
|---|---|
Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
Topics: Adult; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Dextrorphan; Female; Half-Life; Humans; Male; Mixed Function Oxygenases; Phenotype; Quinidine | 1995 |
The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Topics: Adult; Aerosols; Anti-Arrhythmia Agents; Antitussive Agents; Area Under Curve; Capsaicin; Chromatography, High Pressure Liquid; Cough; Cytochrome P-450 CYP2D6; Dextromethorphan; Female; Humans; Male; Matched-Pair Analysis; Polymorphism, Genetic; Quinidine; Reference Values | 1996 |
Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability.
Topics: Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dose-Response Relationship, Drug; Humans; Hydrocodone; Hydromorphone; Quinidine; Substance-Related Disorders | 1997 |
Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan.
Topics: Adult; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Female; Humans; Hyperalgesia; Male; Neurotransmitter Agents; Nociceptors; Pain Threshold; Phenotype; Placebos; Quinidine; Tissue Distribution | 1999 |
The antitussive effect of dextromethorphan in relation to CYP2D6 activity.
Topics: Adolescent; Adult; Antitussive Agents; Cough; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Quinidine; Treatment Outcome | 1999 |
Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Antitussive Agents; Cough; Cross-Over Studies; Dextromethorphan; Dextrorphan; Double-Blind Method; Female; Humans; Male; Quinidine | 2003 |
Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
Topics: Adult; Aged; Analysis of Variance; Dextromethorphan; Drug Combinations; Female; Humans; Male; Middle Aged; Quinidine | 2004 |
Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Double-Blind Method; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Humans; Male; Metabolic Clearance Rate; Middle Aged; Pseudobulbar Palsy; Quinidine; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2004 |
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
Topics: Affect; Aged; Crying; Dextromethorphan; Double-Blind Method; Drug Combinations; Excitatory Amino Acid Antagonists; Female; Humans; Laughter; Male; Middle Aged; Multiple Sclerosis; Pain Measurement; Quality of Life; Quinidine | 2006 |
Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.
Topics: Adult; Aged; Analgesics, Opioid; Chromatography, Liquid; Dextromethorphan; Diabetic Neuropathies; Dose-Response Relationship, Drug; Female; Humans; Male; Mass Spectrometry; Middle Aged; Pain; Quinidine | 2006 |
Effect of metabolic blockade on the psychoactive effects of dextromethorphan.
Topics: Adolescent; Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Pain Measurement; Quinidine; Single-Blind Method; Young Adult | 2010 |
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
Topics: Adolescent; Adult; Affective Symptoms; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Dextromethorphan; Dose-Response Relationship, Drug; Drug Combinations; Electrocardiography; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Oxygen; Quinidine | 2010 |
Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.
Topics: Adult; Affective Symptoms; Dextromethorphan; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Middle Aged; Paroxetine; Quinidine | 2012 |
Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Dextromethorphan; Diabetic Neuropathies; Double-Blind Method; Drug Combinations; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Placebos; Quinidine | 2012 |
A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers.
Topics: Adult; Dextromethorphan; Female; Humans; Male; Memantine; Middle Aged; Quinidine; Reference Values | 2012 |
Influence of CYP2D6 activity on pre-emptive analgesia by the N-methyl-D-aspartate antagonist dextromethorphan in a randomized controlled trial of acute pain.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Cytochrome P-450 CYP2D6; Dextromethorphan; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Genotype; Humans; Male; Middle Aged; N-Methylaspartate; Pain Measurement; Pain, Postoperative; Quinidine; Young Adult | 2013 |
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
Topics: Adolescent; Adult; Affective Symptoms; Aged; Aged, 80 and over; Cohort Studies; Crying; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Drug Combinations; Excitatory Amino Acid Antagonists; Female; Humans; Laughter; Male; Middle Aged; Pseudobulbar Palsy; Quinidine; Treatment Outcome; Young Adult | 2014 |
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
Topics: Aged; Brain Injuries, Traumatic; Dementia; Dextromethorphan; Drug Administration Schedule; Drug Combinations; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Pseudobulbar Palsy; Quinidine; Severity of Illness Index; Stroke; Treatment Outcome | 2016 |
Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Cross-Over Studies; Dextromethorphan; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Quinidine | 2017 |
Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Dextromethorphan; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pilot Projects; Quinidine | 2017 |
Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial.
Topics: Adult; Antidepressive Agents; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dextromethorphan; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Proof of Concept Study; Quinidine; Treatment Outcome | 2017 |
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.
Topics: Adult; Brain Injuries, Traumatic; Dextromethorphan; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injury Severity Score; Male; Maximum Tolerated Dose; Middle Aged; Neuropsychological Tests; Patient Safety; Patient Selection; Prognosis; Prospective Studies; Pseudobulbar Palsy; Quinidine; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2018 |
A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism.
Topics: Adolescent; Adult; Aggression; Autistic Disorder; Cross-Over Studies; Dextromethorphan; Dopamine Antagonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Irritable Mood; Male; Middle Aged; Pilot Projects; Quinidine; Treatment Outcome; Young Adult | 2020 |
70 other study(ies) available for quinidine and dextromethorphan
| Article | Year |
|---|---|
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
Topics: Alcohol Oxidoreductases; Amino Acid Sequence; Animals; Aryl Hydrocarbon Hydroxylases; Binding Sites; Coumarins; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Enzyme Inhibitors; Humans; Isoenzymes; Kinetics; Ligands; Mixed Function Oxygenases; Models, Molecular; Molecular Sequence Data; Protein Binding; Quinidine; Quinine; Rabbits; Rats; Sequence Homology, Amino Acid; Sparteine; Species Specificity | 2003 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis.
Topics: Administration, Oral; Animals; Arthritis; Cells, Cultured; Dimerization; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Development; Enzyme Inhibitors; Freund's Adjuvant; Humans; Lipopolysaccharides; Male; Mice; Molecular Structure; Nitric Oxide; Nitric Oxide Synthase Type II; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley; RAW 264.7 Cells; Structure-Activity Relationship | 2021 |
Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Biological Availability; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Dextromethorphan; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Mixed Function Oxygenases; Quinidine | 1992 |
Metabolic activation of the new tricyclic antidepressant tianeptine by human liver cytochrome P450.
Topics: Antidepressive Agents, Tricyclic; Biotransformation; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Glutathione; Humans; Isoenzymes; Microsomes, Liver; NADP; Oxygen; Piperonyl Butoxide; Pyridines; Quinidine; Troleandomycin | 1990 |
Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites.
Topics: Anti-Arrhythmia Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Kinetics; Microsomes; Microsomes, Liver; Mixed Function Oxygenases; Quinidine; Recombinant Proteins; Saccharomyces cerevisiae; Substrate Specificity | 1995 |
Stereoselective hydroxylation of mexiletine in human liver microsomes: implication of P450IID6--a preliminary report.
Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Hydroxylation; In Vitro Techniques; Mexiletine; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Polymorphism, Genetic; Quinidine; Stereoisomerism | 1993 |
The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.
Topics: Autoantibodies; Binding, Competitive; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Dextromethorphan; Dextropropoxyphene; Dextrorphan; Humans; In Vitro Techniques; Methadone; Methylation; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Perhexiline; Phenotype; Quinidine | 1994 |
Dextromethorphan metabolism in rat: interstrain differences and the fate of individually administered oxidative metabolites.
Topics: Animals; Biotransformation; Dealkylation; Dextromethorphan; Female; Male; Oxidation-Reduction; Quinidine; Quinine; Rats; Rats, Inbred Strains; Species Specificity; Tissue Distribution | 1994 |
Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Topics: Adult; Anti-Arrhythmia Agents; China; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Dextromethorphan; Female; Genotype; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mixed Function Oxygenases; Phenotype; Quinidine; Renal Dialysis; Saliva; Taiwan | 1996 |
Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1.
Topics: Animals; Antitussive Agents; Benzoflavones; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Ditiocarb; Enzyme Inhibitors; Humans; In Vitro Techniques; Methylation; Microsomes, Liver; Mixed Function Oxygenases; Quinidine; Rats; Sulfaphenazole; Tissue Donors | 1997 |
Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
Topics: Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Dextrorphan; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Humans; Microsomes, Liver; Mixed Function Oxygenases; Oxidoreductases, N-Demethylating; Quinidine; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Sulfaphenazole; Transfection | 1998 |
Rates of metabolism of chlorzoxazone, dextromethorphan, 7-ethoxycoumarin, imipramine, quinidine, testosterone and verapamil by fresh and cryopreserved rat liver slices, and some comparisons with microsomes.
Topics: Animals; Antidepressive Agents; Antimalarials; Antitussive Agents; Calcium Channel Blockers; Cell Survival; Chlorzoxazone; Coloring Agents; Coumarins; Cryopreservation; Cytochrome P-450 Enzyme System; Dextromethorphan; Imipramine; In Vitro Techniques; Liver; Male; Microsomes, Liver; Muscle Relaxants, Central; Oxazines; Pharmaceutical Preparations; Pharmacokinetics; Quinidine; Rats; Rats, Sprague-Dawley; Subcellular Fractions; Testosterone; Verapamil; Xanthenes | 2003 |
Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes.
Topics: Animals; Benzoflavones; Carbon Radioisotopes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Enzyme Inhibitors; Hepatocytes; Inhibitory Concentration 50; Kinetics; Male; Methylation; Microsomes, Liver; Oxidoreductases, O-Demethylating; Protein Binding; Quinidine; Quinine; Rats; Rats, Sprague-Dawley; Sulfaphenazole; Troleandomycin | 2003 |
Influence of concomitant quinidine administration on dextromethorphan disposition in rats.
Topics: Animals; Antitussive Agents; Area Under Curve; Dextromethorphan; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Male; Metabolic Clearance Rate; Quinidine; Rats; Rats, Sprague-Dawley | 2004 |
Treatment of emotional lability in ALS.
Topics: Affective Symptoms; Amyotrophic Lateral Sclerosis; Animals; Dextromethorphan; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Humans; Quinidine; Randomized Controlled Trials as Topic | 2005 |
A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes.
Topics: Algorithms; Animals; Antitussive Agents; Chlorpromazine; Chromatography, Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Enzyme Inhibitors; Half-Life; Humans; Hypnotics and Sedatives; In Vitro Techniques; Indicators and Reagents; Isoenzymes; Microsomes, Liver; Midazolam; Pharmaceutical Preparations; Primaquine; Quinidine; Rats; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2005 |
Treatment of pseudobulbar affect in ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Brain Chemistry; Dextromethorphan; Disease Models, Animal; Drug Combinations; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Humans; Pseudobulbar Palsy; Quinidine; Serotonin | 2005 |
Treatment of pseudobulbar affect in ALS: October 26 highlight and commentary.
Topics: Amyotrophic Lateral Sclerosis; Antitussive Agents; Clinical Trials as Topic; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Resistance; Drug Synergism; Enzyme Inhibitors; Genetic Testing; Genotype; Humans; Pseudobulbar Palsy; Quinidine | 2005 |
Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers.
Topics: Cryopreservation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Hepatocytes; Humans; Quinidine | 2005 |
Therapeutic options for emotional lability: current and emerging treatments.
Topics: Antidepressive Agents; Dextromethorphan; Drug Interactions; Humans; Mood Disorders; Pseudobulbar Palsy; Quinidine; Randomized Controlled Trials as Topic | 2005 |
Expression, purification, and characterization of mouse CYP2d22.
Topics: Amino Acid Sequence; Animals; Baculoviridae; Cell Line; Cloning, Molecular; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Dealkylation; Dextromethorphan; Enzyme Inhibitors; Fluoxetine; Insecta; Ketoconazole; Kinetics; Methadone; Mice; Molecular Sequence Data; Molecular Weight; Quinidine; Sequence Homology, Amino Acid; Substrate Specificity | 2006 |
The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.
Topics: Catalase; Chromatography, High Pressure Liquid; Cimetidine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Dextrorphan; Dose-Response Relationship, Drug; Edetic Acid; Enzyme Inhibitors; Humans; Kinetics; Microsomes, Liver; NADP; Oxidoreductases, O-Demethylating; Quinidine; Recombinant Proteins; Superoxide Dismutase; Triazoles | 2004 |
Marketing and drug costs: who is laughing and crying?
Topics: Affective Symptoms; Dextromethorphan; Drug Combinations; Drug Costs; Drug Industry; Humans; Laughter; Marketing; Quinidine; Smiling | 2007 |
Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA).
Topics: Algorithms; Cell Count; Cell Survival; Cryopreservation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Enzyme Inhibitors; Enzyme Stability; Hepatocytes; Humans; Kinetics; N-Methyl-3,4-methylenedioxyamphetamine; Quinidine; Time Factors | 2007 |
Microbial transformation of dextromethorphan by Cunninghamella blakesleeana AS 3.153.
Topics: Analgesics, Opioid; Biotransformation; Chromatography, Liquid; Cunninghamella; Dextromethorphan; Quinidine; Spectrometry, Mass, Electrospray Ionization | 2007 |
Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Topics: Adrenergic beta-Antagonists; Aryl Hydrocarbon Hydroxylases; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dealkylation; Dextromethorphan; Drug Interactions; Enzyme Inhibitors; Fluvoxamine; Humans; Hydroxylation; In Vitro Techniques; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Models, Biological; Molecular Structure; Oxidation-Reduction; Quinidine; Recombinant Proteins; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Timolol | 2007 |
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Topics: Atomoxetine Hydrochloride; Cocaine; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dextromethorphan; Enzyme Inhibitors; Ethanolamines; Fluoxetine; Humans; Hydroxylation; Imipramine; Kinetics; Microsomes; Molecular Structure; Nortriptyline; Polymorphism, Single Nucleotide; Propylamines; Quinidine; Recombinant Proteins; Thioridazine; Tramadol | 2007 |
The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol.
Topics: Biotransformation; Cells, Cultured; Central Nervous System Depressants; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Enzyme Inhibitors; Ethanol; Humans; Kinetics; Plant Extracts; Plant Preparations; Quinidine | 2007 |
It's nothing to laugh about: understanding disorders of emotional expression.
Topics: Affective Symptoms; Antidepressive Agents; Crying; Dextromethorphan; Diagnosis, Differential; Dopamine Agents; Drug Combinations; Excitatory Amino Acid Antagonists; Expressed Emotion; Humans; Laughter; Levodopa; Quinidine; Treatment Outcome; Volition | 2007 |
Brain levels of dextromethorphan and the intensity of opioid withdrawal in mice.
Topics: Animals; Brain; Dextromethorphan; Dextrorphan; Dose-Response Relationship, Drug; Drug Synergism; Male; Mastication; Mice; Mice, Inbred C57BL; Morphine; Morphine Dependence; Motor Activity; Naloxone; Narcotic Antagonists; Quinidine; Stereotyped Behavior; Substance Withdrawal Syndrome | 2008 |
Development of an in-capillary approach to nanoscale automated in vitro cytochromes p450 assays.
Topics: Autoanalysis; Chromatography, High Pressure Liquid; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Fluoxetine; Humans; Isoenzymes; Mass Spectrometry; Pharmaceutical Preparations; Quinidine; Recombinant Proteins; Solutions; Venlafaxine Hydrochloride | 2009 |
Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect.
Topics: Acoustic Stimulation; Adult; Dextromethorphan; Evoked Potentials, Auditory; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Pseudobulbar Palsy; Psychomotor Performance; Quinidine | 2009 |
Involuntary emotional expression disorder in Alzheimer's disease - psychopharmacotherapy aspects.
Topics: Affective Symptoms; Alzheimer Disease; Clinical Trials as Topic; Combined Modality Therapy; Croatia; Crying; Dextromethorphan; Drug Approval; Drug Combinations; Expressed Emotion; Humans; Laughter; Psychotropic Drugs; Quinidine; United States | 2009 |
Dextromethorphan/quinidine (Nuedexta) for pseudobulbar affect.
Topics: Dextromethorphan; Drug Combinations; Drug Interactions; Humans; Pseudobulbar Palsy; Quinidine | 2011 |
Molecular docking and enzyme kinetic studies of dihydrotanshinone on metabolism of a model CYP2D6 probe substrate in human liver microsomes.
Topics: Abietanes; Amino Acids; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Drugs, Chinese Herbal; Herb-Drug Interactions; Humans; Kinetics; Microsomes, Liver; Phenanthrolines; Protein Binding; Quinidine; Salvia miltiorrhiza | 2012 |
Mechanism of action of dextromethorphan/quinidine:comparison with ketamine.
Topics: Dextromethorphan; Drug Combinations; Excitatory Amino Acid Antagonists; Humans; Ketamine; Mood Disorders; Quinidine | 2013 |
Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes.
Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Drug Interactions; Female; Humans; Male; Metabolic Clearance Rate; Microsomes, Liver; Quinidine; Succinates | 2014 |
Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan.
Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Dose-Response Relationship, Drug; Ethylenediamines; Excitatory Amino Acid Antagonists; Ketamine; Kinetics; Male; Mice; Piperazines; Protein Binding; Quinidine; Receptors, N-Methyl-D-Aspartate; Receptors, sigma; Sigma-1 Receptor; Swimming | 2014 |
The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS.
Topics: Adult; Bipolar Disorder; Dextromethorphan; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Middle Aged; Quinidine; Retrospective Studies | 2014 |
CRPS-related neurogenic edema responsive to dextromethorphan/quinidine.
Topics: Adult; Causalgia; Dextromethorphan; Drug Combinations; Edema; Female; Humans; Leg; Quinidine | 2014 |
Intravenous dextromethorphan/quinidine inhibits activity of dura-sensitive spinal trigeminal neurons in rats.
Topics: Animals; Dextromethorphan; Dura Mater; Electric Stimulation; Infusions, Intravenous; Male; Neurons; Nociception; Quinidine; Rats; Rats, Wistar; Spinal Cord; Trigeminal Nerve | 2015 |
Guanfu base A, an antiarrhythmic alkaloid of Aconitum coreanum, Is a CYP2D6 inhibitor of human, monkey, and dog isoforms.
Topics: Aconitum; Alkaloids; Animals; Anti-Arrhythmia Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Dogs; Drug Interactions; Female; Haplorhini; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Mice; Microsomes, Liver; Protein Isoforms; Quinidine; Rats | 2015 |
Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Dextromethorphan; Disease Models, Animal; Excitatory Amino Acid Antagonists; Hindlimb Suspension; Imipramine; Ketamine; Male; Mice; Quinidine; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Swimming | 2015 |
Combination drug shows promise for treating agitation in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Dextromethorphan; Female; Humans; Male; Psychomotor Agitation; Quinidine | 2015 |
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Dementia, Vascular; Dextromethorphan; Diarrhea; Drug Combinations; Excitatory Amino Acid Antagonists; Female; Frontotemporal Dementia; Headache; Humans; Lewy Body Disease; Male; Middle Aged; Pseudobulbar Palsy; Quinidine; Urinary Tract Infections | 2016 |
Dextromethorphan and quinidine are suitable for off-label short-term treatment of agitation in people with Alzheimer's disease following first-line non-drug approaches.
Topics: Alzheimer Disease; Dextromethorphan; Female; Humans; Male; Psychomotor Agitation; Quinidine | 2016 |
NueDexta: A Treatment for Pseudobulbar Affect.
Topics: Affective Symptoms; Dextromethorphan; Drug Combinations; Excitatory Amino Acid Antagonists; Humans; Pseudobulbar Palsy; Quinidine | 2015 |
Dextromethorphan/quinidine withdrawal-emergent catatonia.
Topics: Aged; Catatonia; Dextromethorphan; Drug Combinations; Excitatory Amino Acid Antagonists; Humans; Male; Psychotic Disorders; Quinidine; Receptors, N-Methyl-D-Aspartate | 2016 |
How in vitro influences in silico utilized for the prediction of in vivo - pilot study of the drug-induced pro-arrhythmic potency prediction.
Topics: Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Dextromethorphan; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; In Vitro Techniques; Ketoconazole; Models, Cardiovascular; Patch-Clamp Techniques; Pilot Projects; Quinidine; Terfenadine | 2015 |
Dextromethorphan-Quinidine for Agitation in Alzheimer Disease.
Topics: Alzheimer Disease; Dextromethorphan; Female; Humans; Male; Psychomotor Agitation; Quinidine | 2016 |
Dextromethorphan-Quinidine for Agitation in Alzheimer Disease--Reply.
Topics: Alzheimer Disease; Dextromethorphan; Female; Humans; Male; Psychomotor Agitation; Quinidine | 2016 |
Therapeutic Approach of a High Functioning Individual With Traumatic Brain Injury and Subsequent Emotional Volatility With Features of Pathological Laughter and Crying With Dextromethorphan/Quinidine.
Topics: Adult; Affective Symptoms; Brain Concussion; Brain Injuries; Crying; Dextromethorphan; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Laughter; Male; Quinidine; Stress Disorders, Post-Traumatic | 2016 |
Dextromethorphan-quinidine-responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression?
Topics: Dextromethorphan; Drug Combinations; Emotions; Excitatory Amino Acid Antagonists; Humans; Models, Theoretical; Pseudobulbar Palsy; Psychopharmacology; Quinidine; Receptors, Glutamate; Receptors, Serotonin; Receptors, sigma | 2016 |
Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients.
Topics: Aged, 80 and over; Crying; Dextromethorphan; Drug Combinations; Female; Hospice Care; Humans; Laughter; Male; Medical Audit; Pseudobulbar Palsy; Quinidine; Retrospective Studies; Treatment Outcome | 2017 |
Consequences of daily corticosteroid dosing with or without pre-treatment with quinidine on the in vivo cytochrome P450 2D (CYP2D) enzyme in rats: effect on O-demethylation activity of dextromethorphan and expression levels of CYP2D1 mRNA.
Topics: Adrenal Cortex Hormones; Animals; Cytochrome P450 Family 2; Demethylation; Dextromethorphan; Enzyme Inhibitors; Quinidine; Rats | 2018 |
Effectiveness of Dextromethorphan/Quinidine in Frontotemporal Dementia.
Topics: Aggression; Dextromethorphan; Frontotemporal Dementia; Humans; Male; Middle Aged; Quinidine | 2018 |
Efficacy of Dextromethorphan/Quinidine for Patients With Psychosis-Related Aggression: A Retrospective Case Series.
Topics: Aged; Aggression; Dextromethorphan; Drug Combinations; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Humans; Impulsive Behavior; Male; Middle Aged; Outcome Assessment, Health Care; Psychotic Disorders; Quinidine; Retrospective Studies | 2018 |
Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Dextromethorphan; Drug Combinations; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Quinidine; Speech | 2018 |
Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.
Topics: Aged; Amyotrophic Lateral Sclerosis; Dementia; Dextromethorphan; Drug Combinations; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Parkinson Disease; Pseudobulbar Palsy; Quinidine; United States; United States Food and Drug Administration | 2019 |
Effect of dextromethorphan/quinidine on pentylenetetrazole- induced clonic and tonic seizure thresholds in mice.
Topics: Animals; Anticonvulsants; Dextromethorphan; Dose-Response Relationship, Drug; Male; Mice; Pentylenetetrazole; Quinidine; Receptors, N-Methyl-D-Aspartate; Seizures | 2020 |
KCNT1-positive epilepsy of infancy with migrating focal seizures successfully treated with nonnarcotic antitussive drugs after treatment failure with quinidine: A case report.
Topics: Antitussive Agents; Dextromethorphan; Electroencephalography; Epilepsy; Humans; Infant; Magnetic Resonance Imaging; Male; Mutation; Nerve Tissue Proteins; Piperidines; Potassium Channels, Sodium-Activated; Quinidine; Seizures; Treatment Failure; Treatment Outcome | 2020 |
Assessment of the rapid and sustained antidepressant-like effects of dextromethorphan in mice.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cytochrome P-450 CYP2D6 Inhibitors; Depression; Depressive Disorder, Major; Dextromethorphan; Hindlimb Suspension; Locomotion; Male; Mice; Mice, Inbred C57BL; Open Field Test; Quinidine; Time Factors | 2020 |
Treatment of pseudobulbar affect (PBA) in a patient with a history of traumatic brain injury, partial brain resection, and brainstem stroke: a case report.
Topics: Brain; Brain Injuries, Traumatic; Brain Stem Infarctions; Dextromethorphan; Humans; Male; Middle Aged; Quinidine | 2020 |
Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Dextromethorphan; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Quinidine; Respiratory Insufficiency; Time Factors; Treatment Outcome | 2021 |
Dextromethorphan: From Cough Suppressant to Antidepressant.
Topics: Antidepressive Agents; Antitussive Agents; Depressive Disorder, Major; Dextromethorphan; Humans; Quinidine | 2022 |
Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Deglutition; Dextromethorphan; Humans; Quinidine; Speech | 2023 |